Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 11/20 | 0.57 |
| ▸ | JAK3 | P52333 | 11/20 | 0.57 |
| ▸ | JAK2 | O60674 | 10/20 | 0.57 |
| ▸ | JAK1 | P23458 | 10/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23878992 | 0.94 | AURKA (0.59) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL23878859 | 0.90 | JAK1 (0.69) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL22054014 | 0.90 | JAK1 (0.69) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL22054016 | 0.88 | JAK2 (0.53) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL22054021 | 0.88 | JAK2 (0.66) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL22054065 | 0.88 | AURKA (0.53) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL23889701 | 0.88 | JAK2 (0.66) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL23878801 | 0.88 | JAK2 (0.53) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL23879140 | 0.88 | JAK2 (0.66) | AURKASRCGSK3BTYK2JAK3 | |
| SCHEMBL30147209 | 0.88 | AURKA (0.53) | AURKASRCGSK3BTYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | AURKA 1417/4885SRC 301/4885GSK3B 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.